Two Sigma Advisers’s Trillium Therapeutics TRIL Stock Holding History
Bought
Maintained
Sold
Other funds holding TRIL
Two Sigma Advisers's TRIL Position: Q4 2021 in Review
Two Sigma Advisers sold out of Trillium Therapeutics (TRIL) in Q4 2021, closing a stake of 47,000 shares — an estimated $825K sold.
Two Sigma Advisers first reported a position in TRIL in Q3 2019 and held it in 9 quarters. The position peaked at $4.01M in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Two Sigma Advisers reported no remaining Trillium Therapeutics position as of Q4 2021 after selling out during the quarter.
- Two Sigma Advisers sold 47,000 Trillium Therapeutics shares in Q4 2021, an estimated $825K.
- Two Sigma Advisers first reported a position in Trillium Therapeutics in Q3 2019 and held it in 9 quarters.
- Two Sigma Advisers's Trillium Therapeutics position peaked at $4.01M in Q3 2020.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics as of Q4 2021.
Based on Two Sigma Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.